Format

Send to

Choose Destination
Semin Cancer Biol. 2019 Jun 1. pii: S1044-579X(19)30009-4. doi: 10.1016/j.semcancer.2019.05.021. [Epub ahead of print]

MicroRNA heterogeneity in melanoma progression.

Author information

1
Department of Pharmacology and Toxicology, Boonshoft School of Medicine at Wright State University, Dayton, OH, USA.
2
Departments of Anatomic Pathology & Tumor Biology at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
3
Department of Pharmacology and Toxicology, Boonshoft School of Medicine at Wright State University, Dayton, OH, USA. Electronic address: ravi.sahu@wright.edu.

Abstract

The altered expression of miRNAs has been linked with neocarcinogenesis or the development of human malignancies including melanoma. Of significance, multiple clinical studies have documented that distinct sets of microRNAs (miRNAs) could be utilized as prognostic biomarkers for cancer development or predict the outcomes of treatment responses. To that end, an in-depth validation of such differentially expressed miRNAs is necessary in diverse settings of cancer patients in order to devise novel approaches to control tumor growth and/or enhance the efficacy of clinically-relevant therapeutic options. Moreover, considering the heterogeneity and sophisticated regulation of miRNAs, the precise delineation of their cellular targets could also be explored to design personalized medicine. Given the significance of miRNAs in regulating several key cellular processes of tumor cells including cell cycle progression and apoptosis, we review the findings of such miRNAs implicated in melanoma tumorigenesis. Understanding the novel mechanistic insights of such miRNAs will be useful for developing diagnostic or prognostic biomarkers or devising future therapeutic intervention for malignant melanoma.

KEYWORDS:

Melanoma; Signaling pathways; miRNA

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center